A Phase 2 interventional study of CM310 and Placebo in Chronic Rhinosinusitis (Diagnosis) and Nasal Polyps, sponsored by Keymed Biosciences Co.Ltd. Completed at 19 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.
Among the 46 studies in Nasal Polyps with a site in China, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 2, and was the 11th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–65
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 15 · Phase 4 4
First in 2010; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is close to the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 90 across the 43 interventional studies, 146 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 46 have an industry lead sponsor. The 10 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Keymed Biosciences Co.Ltd has 4 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
6 of the studies in Nasal Polyps with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT07107256Phase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | 2027-03 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07313917Longbio PharmaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2027-02-28 |
| NCT07755371AkesoA Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 46 studies in Nasal Polyps with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of CM310 in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
The study consists of a Screening/run-in Period (up to 4 weeks), a Randomized, Double Blind Treatment Period (16 weeks, till End-of-Treatment Visit) and a Safety Follow-up Period (8 weeks, till End-of-Study Visit).
56 patients who meet eligibility criteria will be randomized 1:1 to receive either CM310 300mg or matched placebo subcutaneously every two weeks (Q2W) for a total of 8 times. All patients will receive MFNS on a daily basis as a background treatment throughout the study. MFNS is required to use no less than 14 days during Screening/run-in Period.
Central reading will be implemented to nasal endoscopic nasal polyp score (NPS) , CT scans to Lund-Mackay score and volume of the involved area of nasosinusitis on 3D-construction images, and nasal polyp biopsy tissue analysis to eosinophil counts \& percentage.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
This study's enrollment of 56 is close to the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Browse Nasal Polyps studies →Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Compared within Nasal Polyps, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
Biological: CM310
Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.
Biological: Placebo
300 mg every two weeks
300 mg every two weeks
Bilateral endoscopic Nasal Polyps Score (NPS)
Change from baseline in the bilateral endoscopic NPS.NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.
Time frame: at Week 16
Nasal Congestion/Obstruction SymptomSeverity (NCS) Score
Change from baseline in the NCS score. NCS score (0-3), higher score means worse nasal symptom.
Time frame: at Week 16
Time to the first response of NPS
Time to the first response of NPS (defined as bilateral endoscopic NPS improved ≥1).
Time frame: Baseline up to Week 24
Lund-Mackay score
Change from baseline in the Lund-Mackay score on CT scan. The range of LM score is 0-24. Higher score means worse nasosinusitis.
Time frame: at Week 16
Volume of the involved area of nasosinusitis on 3D-construction CT scan
Change from baseline in the volume of the involved area of nasosinusitis on 3D-construction CT scan.
Time frame: at Week 16
Bilateral endoscopic NPS
Change from baseline in the bilateral endoscopic NPS.
Time frame: at Week 8
Proportion of subjects receiving rescue therapy for nasal polyps
Proportion of subjects receiving rescue therapy for nasal polyps.
Time frame: Baseline up to Week 24
University of Pennsylvania Smell Identification Test (UPSIT)
Change from baseline in UPSIT. UPSIT score (0-40). Higher score means better sense of smell.
Time frame: at Week 16
22-item Sino-nasal Outcome Test Scores(SNOT-22) score
Change from baseline in SNOT-22 score. SNOT-22 score (0-110). Higher score means a worse outcome.
Time frame: at Week 16
Total Symptom Score(TSS) score
Change from baseline in TSS score. TSS score (0-9). Higher score means worse nasal symptom.
Time frame: at Week 16
Bilateral endoscopic NPS
Change from baseline in the bilateral endoscopic NPS in subjects with concurrent asthma.
Time frame: at Week 16
Bilateral endoscopic NCS
Change from baseline in the NCS in subjects with concurrent asthma.
Time frame: at Week 16
Safety parameters
Incidence of treatment-emergent adverse events (TEAEs), of treatment-emergent serious AEs (TESAEs), etc.
Time frame: Baseline up to Week 24
Pharmacokinetics(PK)
Trough concentration and exposure.
Time frame: Baseline up to Week 24
Pharmacodynamics(PD)
Change from baseline in serum biomarker level (TARC, total IgE and eosinophil level).
Time frame: Baseline up to Week 24
PD(eosinophil level in nasal polyps biospy tissue)
Change from baseline of eosinophil level in nasal polyps biospy tissue.
Time frame: at Week 16
Anti-drug antibodies(ADA)
Incidence of ADA.
Time frame: Baseline up to Week 24
Neutralizing antibody (Nab)
Incidence of Nab.
Time frame: Baseline up to Week 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Mar 2022, 11 months.
Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart